NHS England Rolls Out 5-Session Prostate Radiotherapy for 3,500 Men a Year
Updated
Updated · BBC.com · Jun 9
NHS England Rolls Out 5-Session Prostate Radiotherapy for 3,500 Men a Year
3 articles · Updated · BBC.com · Jun 9
Summary
48 radiotherapy centres in England are expected to begin offering SABR within weeks for low- and intermediate-risk prostate cancer patients, cutting standard treatment from 20 sessions to five.
SABR uses highly focused radiation beams to hit tumors more precisely than conventional radiotherapy, with NHS cancer leaders saying it should reduce side-effects by limiting damage to healthy tissue.
17,500 of the 55,000 men diagnosed with prostate cancer each year fall into the eligible risk groups, and NHS England estimates about 3,500 will choose the treatment because many low-risk patients still opt for active monitoring.
The rollout marks the first routine use of SABR for these prostate cancer patients outside clinical trials; studies are already testing whether it can also be expanded to high-risk cases.
As this new cancer therapy rolls out, are its hidden risks being ignored?
This 'godsend' cancer therapy is here, but who are the thousands of men who won't qualify?
The UK champions a cancer breakthrough, but its research funding is collapsing. Is this progress sustainable?
Revolutionizing Prostate Cancer Treatment: Nationwide Implementation of 5-Session SABR by NHS England
Overview
NHS England has launched a new 5-session Stereotactic Ablative Radiotherapy (SABR) treatment for prostate cancer, marking a major step forward in cancer care. SABR uses advanced technology to deliver highly targeted radiation from multiple angles, allowing a high dose to the tumor while protecting healthy tissues. This approach, known as hypofractionation, means patients need fewer treatment sessions. The rollout is supported by significant investment in new equipment and guided by clear eligibility criteria and robust policies. Together, these efforts aim to ensure effective implementation and equitable access to this innovative, efficient treatment across the country.